Bullboard - Stock Discussion Forum Arch Biopartners Inc ACHFF

Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Arch Biopartners Dosing of First Patient in Phase II Trial

View:

Post by Betteryear2 on Mar 07, 2024 8:19am

Arch Biopartners Dosing of First Patient in Phase II Trial

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Arch Biopartners Announces Dosing of First Patient in Phase (globenewswire.com)